Deerfield Management Company L.P. Series C Purchases New Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Deerfield Management Company L.P. Series C acquired a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 10,034 shares of the company’s stock, valued at approximately $273,000.

A number of other institutional investors have also recently bought and sold shares of the company. RTW Investments LP boosted its position in shares of Tarsus Pharmaceuticals by 9.4% during the fourth quarter. RTW Investments LP now owns 3,152,341 shares of the company’s stock worth $63,835,000 after purchasing an additional 271,640 shares in the last quarter. Cowen AND Company LLC grew its stake in Tarsus Pharmaceuticals by 3.5% in the second quarter. Cowen AND Company LLC now owns 2,197,385 shares of the company’s stock valued at $59,725,000 after acquiring an additional 74,855 shares during the period. Vanguard Group Inc. increased its holdings in shares of Tarsus Pharmaceuticals by 14.5% in the first quarter. Vanguard Group Inc. now owns 1,826,632 shares of the company’s stock worth $66,398,000 after acquiring an additional 231,131 shares in the last quarter. Jennison Associates LLC acquired a new stake in shares of Tarsus Pharmaceuticals during the first quarter worth about $48,380,000. Finally, Assenagon Asset Management S.A. bought a new position in shares of Tarsus Pharmaceuticals during the 2nd quarter valued at about $28,904,000. Institutional investors and hedge funds own 90.01% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on TARS. William Blair upgraded shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. Oppenheimer restated an “outperform” rating and set a $63.00 price objective (up from $61.00) on shares of Tarsus Pharmaceuticals in a report on Friday, August 9th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $51.60.

Tarsus Pharmaceuticals Price Performance

Shares of TARS opened at $32.51 on Friday. The company has a quick ratio of 6.99, a current ratio of 7.03 and a debt-to-equity ratio of 0.28. Tarsus Pharmaceuticals, Inc. has a twelve month low of $12.57 and a twelve month high of $42.50. The stock has a market capitalization of $1.24 billion, a P/E ratio of -6.82 and a beta of 1.06. The company has a 50 day moving average of $27.96 and a 200-day moving average of $31.00.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.88) earnings per share for the quarter, beating the consensus estimate of ($0.98) by $0.10. The company had revenue of $40.81 million during the quarter, compared to analysts’ expectations of $31.30 million. Tarsus Pharmaceuticals had a negative return on equity of 63.99% and a negative net margin of 180.00%. During the same quarter last year, the company earned ($1.17) EPS. As a group, equities research analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.68 EPS for the current fiscal year.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.